Investment and M&A transaction comps
Beauty And Personal Care Investment & M&A Transaction Comps
Reviewed transaction comps tagged beauty and personal care, including disclosed, estimated and rumored values where source notes or calculation basis are available.
8
Reviewed transactions
6
With price data
5.8x
Median EV or valuation / revenue
14.2x
Median EV or valuation / EBITDA
Sortable transaction comps
Beauty And Personal Care transaction table
Rows with reported value
6 / 8
Acquisition value, USD
USD 6.3B
Investment capital, USD
USD 268M
Median EV or valuation / revenue
5.8x
Select up to 12 rows across filters and pages, then share or export the set.
Selected comparison set
Saved in this browser only. Nothing is written to FundComb data.
Choose transactions from the table to build a quick comparison set.
8 shown of 8 matching transactions. Click any transaction row for more detail.
| Select for comparison | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Beautynova Control | 2024-03-18 | PAI Partners | EUR 330M | 365 | 2.5x | 10.6x | Italy | Estimated 1 source | ||
| La Rosée Minority (20%) | 2023-09-09 | FG Bros | EUR 250M Investment Amount | 268 | 4.5x | 14.2x | - | Confirmed 1 source | ||
| Brand Gallinée Control | 2022-09-28 | Shiseido | Undisclosed | Undisclosed | - | - | - | Confirmed 1 source | ||
| Tula Control | 2022-01-04 | P&G | Undisclosed Undisclosed | Undisclosed | 6.7x | - | United States | Estimated 1 source | ||
| Milk Makeup Control | 2021-11-15 | Waldencast Acquisition Corp. | EUR 337M | 386 | 5.8x | - | US (NY) | Estimated 1 source | ||
| Paula's Choice Control | 2021-06-14 | Unilever | USD 2.0B | 2,000 | 6.7x | 18.0x | - | Estimated 1 source | ||
| Dr. Jart+ Control (33%) | 2019-11-18 | The Estée Lauder Companies | USD 1.9B | 1,902 | 3.8x | - | South Korea | Estimated 1 source | ||
| Filorga Control | 2019-07-11 | Colgate-Palmolive | EUR 1.5B Equity Purchase Price | 1,690 | 8.3x | - | France | Confirmed 4 sources |
FundComb transaction comps are informational only. Values may be estimated, rumored, incomplete or derived from public information and should not be relied upon as financial, investment or valuation advice.